A striking difference between two structurally related anti-estrogen medicines is that tamoxifen is strongly hepatocarcinogenic in the rat, whereas toremifene lacks such activity. To study the basis for this difference, the initiating potential of tamoxifen and toremifene were studied by measurement of rapid induction of hepatocellular altered foci (HAF) that express placental-type glutathione S-transferase in the livers of female Sprague-Dawley (S-D) rats and female Fischer 344 (F344) rats. Both agents were administered by gavage at equimolar doses up to a dose that produced marked weight gain suppression. In rats given the high dose of 40 mg/kg per day tamoxifen continuously for 36 weeks, 75% of S-D rats developed liver neoplasms, in contrast to only 10% of F344 rats. In the S-D strain, tamoxifen produced a tendency to increased HAF at 2 weeks at the dose of 40 mg/kg per day and by 12 weeks, a dose-related increase was evident. In contrast, toremifene induced no HAF even at the equimolar high dose of 42.4 mg/kg per day for 12 weeks. The induction of HAF by tamoxifen was less in the F344 rats. Neither agent elicited increases in hepatocellular proliferation in S-D or F344 rats. When phenobarbital was administered for 24 weeks as a promoting agent after the anti-estrogens, S-D rats given tamoxifen at 20 mg/kg per day for 12 weeks, developed liver neoplasms, but not F344 rats or rats of either strain given even a higher dose (42.4 mg/kg) of toremifene. Thus, tamoxifen has initiating activity in these rat strains whereas toremifene does not.
Introduction
Tamoxifen (TAM*) and toremifene (TOR) are structurally related polyphenylethylene anti-estrogens ( Figure 1 ) used in the treatment of breast cancer. TAM is associated with cancer of the endometrium in treated patients, whereas evidence is inadequate for TOR (1) , which was more recently introduced into medical use.
TAM was shown to be hepatocarcinogenic in rats in both 1-year studies (2-4) and in 2-year studies (5), whereas TOR was not (2, 3, 6) .
The mechanism for the hepatocarcinogenicity of TAM has not yet been elucidated. Several studies have reported a 'promoting' activity when TAM was administered after another carcinogen (7) (8) (9) . TAM and TOR have comparable hormonal effects in rat liver (10) , indicating that this is not the basis for a promoting or carcinogenic effect of TAM (11, 12) , which is further supported by the fact that male and female rats are equally susceptible to carcinogenic effects (5) . Ghia and Mereto (8) reported an initiating effect of TAM in livers of female Sprague-Dawley (S-D) rats in a complex protocol involving dietary administration followed by feeding of 2-acetylaminofluorene and administration of a necrogenic dose of carbon tetrachloride. Carcinogens with initiating activity are typically DNA reactive (13) and, indeed, TAM is established to bind to liver DNA (14) (15) (16) (17) (18) , whereas TOR has little or no such potential (15, 16) . Accordingly, we have postulated that the difference in the carcinogenic activity of the two agents is attributable to differences in DNA binding and initiating activity (11, 12) , as also concluded by others (19) , in contrast to characterization of TAM as a 'promoter' (20) .
To further examine whether initiating activity of TAM could be involved in its carcinogenicity and to determine whether TOR has such activity, we compared the liver initiating activity of these agents measured as rapid induction of preneoplastic lesions and their promotability into neoplasms (21) (22) (23) (24) in two strains of rat, the S-D which is highly susceptible to TAM hepatocarcinogenicity (2) (3) (4) , and the Fischer 344 (F344), which is reported to be resistant (25) . We report that TAM, but not TOR has initiating activity in both strains, which was greater in the S-D strain than in the F344.
Material and methods

Test materials
Tamoxifen (TAM) citrate, (Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,Ndimethylethanamine-2-hydroxy-1,2,3-propane-tricarboxylate and toremifene (TOR) citrate, 2-4-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy-N,Ndimethylamine citrate were obtained from Adria Laboratories (Columbus, OH). The purity of both compounds, as reported by Orion Pharma, was 99%. Phenobarbital sodium (PB) was of Ͼ99% purity and was purchased from Sigma Chemical Co. (St Louis, MO). It was mixed at 500 p.p.m. with NIH-07 powder diet and provided ad libitum for 24 weeks, between weeks 13 and 36, with the exception of high dose TAM groups (groups 5 and 12).
The stability of TAM and TOR, and homogeneity at concentrations up to 9.5 mg/ml have been previously validated (2) . Suspensions of test substances in 0.5% carboxymethyl cellulose (CMC), lot no. 19-F-0022 (Sigma No. C-8758) were prepared weekly, and were stored at 4°C until use. Concentrations in these suspensions were 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml for TAM, and 4.2 mg/ml, 8.4 mg/ml for TOR. The volume of suspension administered was adjusted on the basis of individual body weights. Each daily dose of TAM or TOR was administered by intragastric instillation daily for up to 12 weeks, except with high dose TAM, which was administered for up to 36 weeks to groups 5 and 12. Thus the doses given were 5, 10, 20 or 40 mg/kg for TAM and 21.2 or 42.4 mg/kg for TOR, which are equimolar to the two top doses of TAM.
Bromodeoxyuridine (BrdU), was purchased from Sigma Chemical Co. (St Louis, MO) and was administered to three animals per group, per strain and sacrifice interval by an Alzet osmotic pump, model 2 ML 1, purchased from Alza Corp. (Palo Alto, CA). Minipumps were implanted, 3 days prior to necropsy containing BrdU at a concentration of 20 mg/ml, which delivered a total of 13.8 mg per rat.
Animals
A total of 181 female Crl:CD(BR): Charles River Sprague-Dawley (S-D) rats and 181 female Fischer 344 (F344) rats, of 4 weeks of age, were received from Charles River Laboratories, Kingston, NY. Upon receipt at the American Health Foundation (AHF) the animals were acclimated to laboratory conditions for~2 weeks. The rats were assigned to groups by body weight. Animals were housed at two per cage, in solid-floor cages with standard hardwood commercial rodent bedding, 'Beta Chip'. The holding rooms were maintained at temperature and relative humidity limits of 72 Ϯ 8°F (64-80°F) and 55 Ϯ 15% (40-70%) respectively. Continuous low-level fluorescent lighting was given for 12 h per day, and cage rack rotation was performed every 2 weeks. NIH-07 powder diet (Purina, St Louis, MO) and acidified water provided by a stainless steel distribution system, were available ad libitum. The diet and bedding had a certificate of analysis for standard contaminants. Diet, drinking water and bedding were analyzed for specific contaminants.
All animal maintenance and handling procedures were conducted in accordance with US Department of Agriculture and NIH guidelines for humane care. The study protocol was approved by the Institutional Animal Care and Use Committee prior to commencement. The AHF Research Animals Facility is fully accredited by the American Association for the Accreditation of Laboratory Animal Care. 
Experimental design
The experimental design is given in Table I . A total 362 female S-D and F344 rats were divided into 14 groups. The animals were~4 weeks of age at the time of arrival, and 6 weeks old at the start of dosing. There were two interim sacrifices (at 2 and 12 weeks) and one terminal (at 36 weeks). The doses selected were based on previous published data from this laboratory (2,4). All groups, except groups 5 and 12, received TAM or TOR for the first 12 weeks of the study, followed by 24 weeks of PB (at 500 p.p.m.) in the diet. Groups 5 (S-D) and 12 (F344) received 40 mg/kg per day TAM for 36 weeks to compare the strain response to TAM, which we previously showed to be hepatocarcinogenic to S-D rats (2,4). Since TOR was not carcinogenic (2), a strain comparison was not made. Animals were observed daily for mortality, morbidity, pharmacotoxic effects, general condition and behavior.
Body weights
Individual body weights were recorded at the beginning of the study, weekly for the first 11 weeks, and every 2 weeks for the duration (36 weeks) of the study.
Post-mortem examination
Animals found dead and those killed in extremis or at scheduled sacrifices were submitted to a complete gross post-mortem examination. The liver, kidneys, spleen, stomach, jejunum, colon, uterus, mammary glands, adrenals, pituitary, sternal, femoral, tail bone, bone marrow (sternum) and all grossly observed lesions were sampled for histology. All saved tissues were fixed in 10% neutral buffered formalin (NBF).
Histopathology
All tissue specimens reported at necropsy to be cysts or masses were examined histologically. The livers received detailed sampling, with slices being taken from each of the seven lobes, i.e. anterior right, posterior right, median right, median left, left, anterior caudate and posterior caudate lobes, as described (26) . In the present report, data from liver are presented and evaluated. Liver sections were immuno-histochemically treated with antibodies to bromodeoxyuridine (BrdU) (27) or proliferating cell nuclear antigen (PCNA) (28) , according to established methods as used previously (29) . In histologically normal liver, excluding preneoplastic and neoplastic lesions, between 1200 and 1500 hepatocyte nuclei per liver slide were counted. Based on the above, the replicating fraction (RF) for the liver of each animal was calculated and represented as the percentage of positive nuclei out of the total number of hepatocellular nuclei counted.
Histopathological examination was performed on histochemically stained sections by placental-type glutathione S-transferase (GST-P) of NBF/ethanol fixed tissue (30, 31) . GST-P-positive (GST-P ϩ ) foci of clusters of three or more hepatocytes over the entire evaluated liver area were calculated and expressed in cm 2 . These preneoplastic lesions were quantified using an image analyzer system with microscope (Videoplan, Carl Zeiss, Inc., NY), as previously described (27) .
Statistics
Data were analyzed using Student's t-test for body weight data. The RFs of hepatocytes and the mean number of GST-P ϩ foci/cm 2 in the liver were compared between the study groups by one-way ANOVA. If the test was significant, it was followed by Dunnett's multiple comparisons test, where each group is contrasted with a specified control group. For the GST-P ϩ values of different TAM groups a trend analysis was conducted. For the three scheduled sacrifices, the body weights of two equimolar groups, i.e. 20 and 40 of TAM or 42.4 of TOR, were compared through a one-way ANOVA followed by Tukey's multiple comparison test (32) .
Results
Body weights
All treated groups, in both strains showed reduced body weight gain, compared with their respective control groups (Table II) . At 2 weeks, in the F344 strain, the high dose of TAM produced the sharpest growth rate reduction. In S-D rats, the reduction was similar across all TAM or TOR groups. At 12 weeks, in both strains, the reduction was even more marked, but was comparable across all TAM or TOR groups. At 36 weeks, after cessation of exposure to TAM or TOR at 12 weeks and subsequent administration of PB in the diet for 24 weeks, weight gain was improved. The clearest improvement in both strains was in the TOR exposed groups. At this time, in both strains the high dose TAM groups, which received TAM throughout the experiment, showed the lowest body weight gain pattern.
Hepatocellular replicating fraction
RFs of normal hepatocytes (excluding lesions) scored by either BrdU or PCNA nuclear positivity were comparable in untreated S-D rats at 2, 12 and 36 weeks and in the F344 at 12 weeks (Table III) . No statistically significant increases were found in either strain, in any of the studied groups at any interval with either marker. Interestingly, administration of PB for 24 weeks to control rats (group 1) also did not elevate RFs.
Hepatocellular altered foci
In the S-D rats, a low multiplicity of up to 0.37 GST-P ϩ HAF per cm 2 was present in untreated controls at 2 and 12 weeks (Table IV) . At the 2-week sacrifice, exposures of up to 20 mg/ kg produced no increase, whereas 40 mg/kg TAM resulted in an average of 1.57 HAF/cm 2 , which was not statistically significant, although, in this group of eight rats, two displayed levels that were greater than the highest level of 1.59 in controls. At 12 weeks, the incidence in the high dose TAM group was 7.03/cm 2 , which also was not significantly increased, 
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although all eight rats displayed levels greater than the highest level of 0.14 in controls. In the groups given 10 and 20 mg/ kg, the average incidences were outside the control range and there was a positive trend for increase. TOR at 42.5 mg/kg per day, which was equimolar to the high dose of TAM, produced no increase. At 36 weeks, a substantial increase was present in the high dose group given only TAM and there was a positive trend for increase in the groups given TAM followed by PB. TOR at the high dose followed by PB showed no increase. In F344 rats, only the 12-and 36-week intervals were studied, omitting the 2-week interval because the response was less than in the S-D rats. This strain also exhibited a low frequency of GST-P ϩ HAF in controls (Table V) , which was comparable to that in S-D rats. The dose of 40 mg/kg TAM produced a significant increase at 12 weeks, which, however, was~1/3 the multiplicity in S-D rats. At lower doses, no increase in foci occurred, although there was a positive trend. At 12 weeks, the 42.4 mg/kg dose of TOR, which was equimolar to the high dose of TAM, produced no increase. At 36 weeks, with continuous exposure to the high dose of TAM, foci were substantially increased, but were still only about one-third that of S-D rats. The multiplicity of HAF in the group given the high dose of TOR followed by PB was not increased. Histopathology No evidence of hepatotoxicity was found at any sacrifice interval. At 36 weeks, S-D rats given the high dose continuous TAM displayed basophilic HAF in 100% and clear cell HAF in 75% of the animals (Table VI) . In 75% of these animals, liver neoplasms were present. In the F344 strain, this exposure to TAM induced 100% basophilic HAF and 30% clear cell HAF. Only 10% of these animals developed liver neoplasms. The mid-high TAM dose (20 mg/kg) induced 37% basophilic HAF and 12% clear cell HAF in S-D rats. None were evident in F344 rats. In addition, the 12-week exposure of S-D rats to 20 mg/kg TAM followed by PB resulted in a 12% incidence of hepatic adenomas whereas none were found with 21.2 or 42.4 mg/kg per day exposure to TOR.
Discussion
In this study, we examined the initiating activity in the livers of two strains of female rats of the hepatocarcinogenic anti- a This group was exposed to TAM for 36 weeks, all other groups were exposed to test substance or carrier for 12 weeks, followed by 24 weeks on 500 p.p.m. PB. b The F344 rats were only evaluated at this interval because of low values in S-D rats.
-, Due to the absence of increase in the high dose group, the lower dose groups were not quantified, although scanning suggested no increase. c Percent positive hepatocellular nuclei. a This group was exposed to TAM for 36 weeks, all other groups were exposed to test substance or carrier for 12 weeks, followed by 24 weeks on 500 p.p.m. PB. b HAF per cm 2 . *Significant trend analysis at P Ͻ 0.01; **statistically significant from control at P Ͻ 0.01 by ANOVA followed by Dunnett's multiple comparisons test. a This group was exposed to TAM for 36 weeks, all other groups were exposed to test substance or carrier for 12 weeks, followed by 24 weeks on 500 p.p.m. PB. b HAF per cm 2 ; *, significant trend analysis at P Ͻ 0.01; **statistically significant from control at P Ͻ 0.01 by ANOVA followed by Dunnett's multiple comparisons test.
estrogen TAM (2-5) compared with the non-carcinogenic TOR (2, 4, 6) . The findings support previous observations and document the initiating activity of TAM, which differed in the two strains. The early appearing preneoplastic HAF were quantified as an index of initiating activity (21) (22) (23) (24) . These foci precede the development of neoplasia in experimental hepatocarcinogenesis and are precursors of neoplasms. They greatly exceed the number of liver neoplasms and are quantitatively related to the number of neoplasms. Among many histochemical markers 2250 for HAF, GST-P has proven useful (30,31) and we document for the first time that TAM-induced HAF express this phenotype. In the S-D rats, there was an indication of induction of HAF by TAM at 2 weeks and by 12 weeks, HAF were increased in a dose-related manner. Kim et al. (33) found no GST-P ϩ foci in female S-D rats given TAM at 1 mg/rat per day for 9 weeks, which, however, is lower than the doses used here. In the F344 rats, HAF were significantly increased in the high dose group at 12 weeks, but the multiplicity was~1/3 that in the S-D rats. Dragan et al. (9) did not observe induction of HAF in female F344 when TAM was given as a single dose, but as we have shown, F344 rats are not as sensitive as S-D. At 36 weeks, in both strains and in the high-dose TAM groups, HAF were significantly increased compared with their own controls. The increment in both strains was proportional such that the multiplicity in the S-D rats was still three times higher than that in the F344 rats. TOR at an equimolar dose to the high dose of TAM did not increase HAF in either strain, even after PB promotion. This latter observation cannot be ascribed to an inhibition of GST-P by TOR because Dragan et al. (20) have shown that TOR does not suppress diethylnitrosamineinduced GST-P ϩ HAF. Moreover, we studied groups given TOR followed by PB. Thus, TAM had initiating activity in both strains, which was greater in the S-D. This is consistent with findings in the S-D strain that TAM is strongly hepatocarcinogenic (2-5), but only weakly hepatocarcinogenic in the F344 strain (25) . As further evidence for initiation, the ability of the liver tumor promoter PB to enhance HAF and to elicit tumor development (34) was studied. PB promotion for 24 weeks resulted in an increase in HAF and a low incidence of adenomas in S-D rats given the mid-high (20 mg/kg) dose of TAM for 12 weeks. The lower dose groups exhibited increases in HAF, but no tumors. PB also did not elicit tumor development in the TAM-exposed F344 rats in which lower multiplicities of HAF were present at commencement of promotion. Thus, TAM induced HAF, some of which were promotable to neoplasms, although it appears that a certain multiplicity of HAF is required to provide the substrate for promotion. Promotability of TAM-induced effects was also demonstrated by Carthew et al. (35) who reported that TAM fed in the diet at 420 p.p.m. (~21 mg/kg per day) to Wistar rats for 3 months yielded a 30% incidence of liver tumors within their lifetimes and an 86% incidence when PB was administered subsequently. They did not examine early cellular lesions, as in the present study.
To better quantify the initiating activity of TAM, it would be useful to conduct studies similar to those reported with intervals of exposure of 1-4 weeks. Presently, it appears that some sustained exposure is necessary for initiation. This is similar to the report of initiating activity of another hormonal agent, cyproterone acetate, by Deml et al. (36) .
The preneoplastic TAM-induced changes were not accom-2251 panied by any increase in hepatocellular proliferation. Moreover, there was no evidence of cytotoxic/necrotic effects. Thus, sustained proliferation, which can contribute to hepatocellular neoplasia (37), was not involved in TAM-induced initiation of hepatocarcinogenesis. This is at variance with the report by Carthew et al. (25) , in which increases in PCNA-labeling indices, with 21 mg/kg TAM at 12 weeks, were reported. These increases, however, disappeared, despite continuing TAM exposure, by 26 weeks. This group (38) proposed that the sensitivity of the Wistar and Lewis strains is due to induced cell death and consequent hyperplasia. However, we found no evidence of cell injury and no increased cell proliferation in the livers of the sensitive S-D rats using methods with which we have readily documented increased proliferation in other studies (29) . Thus, enhanced cell proliferation is not the only basis for sensitivity to TAM hepatocarcinogenicity. The absence of increased cell proliferation indicates that the induction of HAF is not due to a 'promoting' effect. Accordingly, we suggest that the main factor in inducing liver foci and neoplasms is the DNA reactivity of TAM (2,14-18). Carthew et al. (25) found that TAM produced greater average levels of adducts in sensitive strains of rats than in the nonsensitive F344 strain. We reported that TAM produced a substantial level of adducts in the S-D rats (16) . For agents, such as TAM, that are DNA reactive, it is not possible to quantify a 'promoting' effect because a DNA-reactive carcinogen given after another one produces a syncarcinogenic effect as a consequence of summation of the DNA damage (39) . Thus, the report that TOR has less 'promoting' activity than TAM (40) more likely reflects the lack of DNA reactivity of TOR (2, 15, 16) .
The present findings extend the information on strain differences in susceptibility to the hepatocarcinogenic effect of TAM. Carthew et al. (25) compared three strains of rat and reported that after 6 months of exposure to 21 mg/kg TAM, both the Wistar and Lewis strains had developed liver carcinoma, whereas the F344 rats developed liver carcinoma only by 20 months. Our findings indicate that the S-D exhibits high sensitivity, like the Wistar and Lewis strains, and the F344 is resistant. The Wistar and Lewis strains have not been studied for initiation by TAM, as reported here for the S-D, but we would predict that they would be susceptible. Since liver cancer is only marginally, if at all, increased in patients receiving TAM (41, 42) , it would appear that the response of the human liver is like that of the resistant rat strains, although other tissues are susceptible (1) . The basis for this difference warrants study. Incidentally, no investigation has been reported on examination for HAF in human liver.
In conclusion, the present findings provide evidence for an initiating activity of TAM in rat liver, which we postulate to be mainly a consequence of DNA reactivity and to be the principal effect leading to hepatocarcinogenicity. In a strain sensitive to TAM, TOR did not exhibit such activity and accordingly was not hepatocarcinogenic. Thus, TAM exhibits the profile of a human cancer hazard (43) .
